One of the WHO’s most important jobs is managing viral outbreaks. The rapid spread of mpox, a disease related to smallpox, is a reminder of its shortcomings.
Although well-intended, the WHO’s overcautious and convoluted regulatory process stalled vaccine delivery for months before an approval was granted last month. Hundreds of lives were lost in the meantime, many of them children.
Mpox, previously called monkeypox, was first discovered in monkeys used for research in 1958. The virus began circulating among humans in western and central Africa more than a decade later. This year, more than 27,000 suspected cases and 800 deaths have been reported in the Democratic Republic of the Congo (DR Congo). A serious outbreak in 2022, which began in Europe and spread to the US, largely subsided last year, although mpox never stopped circulating in the DR Congo.
A new, deadlier and more virulent version of mpox was discovered last year. Like past outbreaks, its symptoms are flu-like and include a rash that can develop into pustules or lesions that cover the body. When these excruciating sores erupt in the mouth and throat, eating can become difficult; some children have died of starvation as a result. Children under 15 make up two-thirds of cases and more than 80 percent of deaths in Africa.
A perfect storm of factors has accelerated the spread of mpox in the DR Congo. Ongoing political violence has displaced millions of people, who have crowded into camps where close contact is difficult to avoid and sex work is common.
Although mpox can spread via sexual contact, it is not considered a sexually transmitted disease.
The country is also battling cholera, malaria and measles.
Public health resources are understandably stretched. Yet the best means of fighting mpox — a safe and effective vaccine, approved by US and European regulators — has been available for years. Why did the WHO take so long to grant its approval and was its separate endorsement necessary?
Low and middle-income countries such as the DR Congo typically depend on UNICEF and global vaccine alliance Gavi to buy and distribute vaccines. Before doing so, the groups must have approval from the WHO, which can either “prequalify” the vaccines — by conducting its own data assessments, inspections and testing — or issue a so-called emergency use listing that would speed access to unlicensed products.
For two years, the WHO took neither path. Despite Congolese officials regularly sharing data with the WHO — and reports that Bavarian Nordic AS, the principal manufacturer, had submitted the research used for its European approval — the organization said it did not have the data required for prequalification.
Meanwhile, an emergency use listing could not be sought until an emergency had been formally declared, which did not happen until August.
Bavarian Nordic, for its part, was left in the dark about procurement commitments from Gavi, which awaited WHO authorization to begin purchase negotiations.
This nest of interdependent approvals would be maddening enough, even if the delays it caused were not so tragic.
The WHO’s instinct to review new data is to some extent understandable. Absent randomized clinical trials, it is hard to assess whether the vaccines approved in Europe and the US are effective against the version of the virus circulating in the DR Congo.
Moreover, giving an unauthorized vaccine to an otherwise healthy population, including children, can be risky. Yet as the virus spreads and the death toll mounts, the benefits of vaccination start to outweigh the potential costs — and the prospect of stalling to replicate lengthy regulatory processes becomes increasingly indefensible.
To its credit, the WHO has stepped up its response over the past month. Vaccine donations from rich countries have started to arrive and, with last month’s announcement, so, too, would purchases from Bavarian Nordic.
Yet the belated resolution must not obscure the need for a nimbler, more straightforward emergency approval process that allows for quick adoption of US and European standards without all the hoops. A similar process has been used successfully for years in Pepfar, the US government program to treat HIV, and should be expanded — if only for the next outbreak. More transparency with manufacturers and other stakeholders throughout the prequalification process would help, too.
The WHO has substantial responsibilities and it should not waste precious time duplicating efforts. By trusting its global partners, it can focus instead on saving lives.
The Editorial Board publishes the views of the editors across a range of national and global affairs.
Would China attack Taiwan during the American lame duck period? For months, there have been worries that Beijing would seek to take advantage of an American president slowed by age and a potentially chaotic transition to make a move on Taiwan. In the wake of an American election that ended without drama, that far-fetched scenario will likely prove purely hypothetical. But there is a crisis brewing elsewhere in Asia — one with which US president-elect Donald Trump may have to deal during his first days in office. Tensions between the Philippines and China in the South China Sea have been at
A nation has several pillars of national defense, among them are military strength, energy and food security, and national unity. Military strength is very much on the forefront of the debate, while several recent editorials have dealt with energy security. National unity and a sense of shared purpose — especially while a powerful, hostile state is becoming increasingly menacing — are problematic, and would continue to be until the nation’s schizophrenia is properly managed. The controversy over the past few days over former navy lieutenant commander Lu Li-shih’s (呂禮詩) usage of the term “our China” during an interview about his attendance
Bo Guagua (薄瓜瓜), the son of former Chinese Communist Party (CCP) Central Committee Politburo member and former Chongqing Municipal Communist Party secretary Bo Xilai (薄熙來), used his British passport to make a low-key entry into Taiwan on a flight originating in Canada. He is set to marry the granddaughter of former political heavyweight Hsu Wen-cheng (許文政), the founder of Luodong Poh-Ai Hospital in Yilan County’s Luodong Township (羅東). Bo Xilai is a former high-ranking CCP official who was once a challenger to Chinese President Xi Jinping (習近平) for the chairmanship of the CCP. That makes Bo Guagua a bona fide “third-generation red”
Historically, in Taiwan, and in present-day China, many people advocate the idea of a “great Chinese nation.” It is not worth arguing with extremists to say that the so-called “great Chinese nation” is a fabricated political myth rather than an academic term. Rather, they should read the following excerpt from Chinese writer Lin Yutang’s (林語堂) book My Country and My People: “It is also inevitable that I should offend many writers about China, especially my own countrymen and great patriots. These great patriots — I have nothing to do with them, for their god is not my god, and their patriotism is
RSS